Melior begins dosing MLR-1023 in Phase IIb trial to treat type 2 diabetes

US-based Melior Pharmaceuticals I has begun dosing in a Phase IIb trial aimed at evaluating the efficacy of MLR-1023, an oral insulin sensitizer, in adult patients with uncontrolled type 2 diabetes on metformin therapy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news